Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) st
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq climbs over 1% as SpaceX, Super Micro improve AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
| Johnson & Johnson (NYSE: JNJ) | Delayed: 256.23 -3.13 (1.21%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $259.36 | 52 Week High | $126.07 | |||
| Open | $257.50 | 52 Week Low | $94.28 | |||
| Day High | $257.75 | P/E | 53.27 | |||
| Day Low | $254.56 | EPS | $4.81 | |||
| Volume | 1,987,014 | |||||
